News | Patient Positioning Radiation Therapy | September 23, 2016

Vision RT Sharing New Clinical Data at ASTRO 2016

University of North Carolina showed no radiation-induced blood flow abnormalities when Align RT used in left breast radiotherapy

Vision RT, AlignRT, clinical data, radiation therapy, ASTRO 2016

September 23, 2016 — Vision RT announced it will be exhibiting at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting Sept. 25-28 in Boston. New data will be released at this meeting from a trial at the National Cancer Institute (NCI)-accredited Lineberger Cancer Center at the University of North Carolina showing zero radiation-induced abnormalities in blood flow to the heart in all patients where Vision RT’s product was used in left breast radiotherapy. This contrasts with a previous study, using a different technique for similar patients, where 27 percent of patients exhibited heart damage.  This data will be presented at an Industry Expert Theater session by Tim Zagar, M.D. At the same session, David Gierga, Ph.D., of Massachusetts General Hospital, will also present on the use of different techniques, including AlignRT, for reproducible breast cancer radiotherapy.

Throughout the meeting there will be live demonstrations on AlignRT for frameless stereotactic radiosurgery (SRS), and for Deep Inspiration Breath Hold (DIBH) breast treatments. Alongside the demonstrations there will be live presentations from clinical experts on the booth, covering breast cancer, stereotactic treatments including frameless SRS, and a variety of other clinical applications.

For more information: www.visionrt.com

Related Content

Videos | Radiation Therapy | February 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...